Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating Oxaliplatin/Bevacizumab and Irinotecan/Cetuximab in pretreated mCRC
NCT00755118Phase 2Terminated
- Sponsor
- University Hospital of Crete
- Start
- Oct 2008
- Primary completion
- Aug 2012
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin, fluorouracil, folinic acid, bevacizumab, irinotecan and 1 more in colorectal cancer (metastatic) (mCRC), sponsored by University Hospital of Crete. Started Oct 2008; status: terminated.
02
Drugs
oxaliplatinfluorouracilfolinic acidbevacizumabirinotecan
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT00755118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00755118.